Difference between revisions of "Corona Vaccins First Dose Efficacy"
From Tech
Jump to navigationJump to search| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
=Pfizer= |
=Pfizer= |
||
| − | [https://www.nejm.org/doi/full/10.1056/nejmoa2034577 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine] |
+ | [https://www.nejm.org/doi/full/10.1056/nejmoa2034577 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine] ([https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19 BNT162b2=Pfizer/BioNTech]) |
| + | |||
| − | [[File:Screenshot_2021-07-11_at_11-28-03_Safety_and_Efficacy_of_the_BNT162b2_mRNA_Covid-19_Vaccine_NEJM.png||Efficacy of BNT162b2 (Pfizer) against Covid-19 after the First Dose.]] |
+ | [[File:Screenshot_2021-07-11_at_11-28-03_Safety_and_Efficacy_of_the_BNT162b2_mRNA_Covid-19_Vaccine_NEJM.png|x200px|Efficacy of BNT162b2 (Pfizer) against Covid-19 after the First Dose.]] |
| + | |||
| + | [https://www.nejm.org/doi/pdf/10.1056/NEJMoa2101765?articleTools=true#page=7 Vaccinated vs Unvaccinated in BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting] |
||
| + | |||
| + | [[File:Screenshot 2021-07-11 at 12-37-30 BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting - NEJMoa2101765.png|x200px]] |
||
=Moderna= |
=Moderna= |
||
| − | [https://www.fda.gov/media/144434/download#page=28 Vaccines and Related Biological Products Advisory Committee MeetingDecember 17, 2020] |
+ | [https://www.fda.gov/media/144434/download#page=28 Vaccines and Related Biological Products Advisory Committee MeetingDecember 17, 2020] |
| + | |||
| ⚫ | |||
| + | |||
| + | =AstraZeneca= |
||
| + | [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963928/UKPAR_COVID_19_Vaccine_AstraZeneca_23.02.2021.pdf Cumulative incidence plot for time to first SARS-CoV-2 virologically-confirmed COVID-19 occurring post dose1] |
||
| + | |||
| + | |||
| + | [[File:Screenshot 2021-07-11 at 13-07-32 Public Assessment Report - UKPAR COVID 19 Vaccine AstraZeneca 23 02 2021 pdf.png|x200px]] |
||
| + | |||
| + | [https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know (Oxford/AstraZeneca COVID-19 vaccine AZD1222)] |
||
| + | |||
| + | =Janssen= |
||
| + | [https://www.nejm.org/doi/full/10.1056/NEJMoa2101544 Cumulative Incidence of Covid-19 with Onset at Least 1 Day after Vaccination and Vaccine Efficacy over Time.] |
||
| + | |||
| + | [[File:Screenshot 2021-07-11 at 14-04-04 Safety and Efficacy of Single-Dose Ad26 COV2 S Vaccine against Covid-19 NEJM.png|x200px]] |
||
| + | =See Also= |
||
| ⚫ | |||
| + | * [[Vaccins]] |
||
| + | * [[Corona]] |
||
